Kornimate/medical-research-clean huggingface dataset:
gemcitabine/vinorelbine versus gemcitabine/cisplatin versus gemcitabine/capecitabine in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: development of an active second-line treatment option for metastatic breast cancer patients previously pre-treated with anthracyclines and taxanes in neoadjuvant, adjuvant or palliative settings. for each randomisation arm, 47 patients will be included. the trial was performed as a 2-stage phase ii study according to the optimal design by simon with overall response rate as the primary objective. study design: arm a gemcitabine 1000 mg/m2 d1, 8; vinorelbine 25 mg/m2 d1, 8 q 3 weeks arm b gemcitabine 1000 mg/m2 d1, 8; cisplain 30 mg/m2 d1, 8 q 3 weeks arm c gemcitabine 1000 mg/m2 d1, 8; capecitabine 1650 mg/m2 oral d1-14 q 3 weeks


Eligibility criteria:
inclusion criteria: * histologically confirmed metastatic breast cancer * all patients were required to give written informed consent * only one prior chemotherapy for metastatic breast cancer was allowed. this clinical trial was designed to test the efficacy of a second-line chemotherapy. * antracycline-pretreatment during aduvant or palliative first line therapy * bidimensionally measurable lesion outside a previous radiation field. * age \>= 18 years * karnofsky performance status \>= 70% * adequate heamatological, renal, cardiac and hepatic function * no radiation of the measurable lesion during the study was allowed. exclusion criteria: * only bone metastases * active infection * previous treatment with one of the study drugs * application of other cytotoxic chemotherapy * insufficent renal function (creatinine clearance \< 60ml/min) * known dpd deficiency * clinically unstable brain metastasis * pregancy or lactation * other primary malignancies (other than carcinoma-in-situ of the cervix or adequately treated basal cell cancer of the skin).

Keywords: gemcitabine vinorelbine cisplatin capecitabine pretreated metastatic breast cancer
respiratory and hemodynamics parameters response to positive end-expiratory pressure

Conditions: Obesity Associated Disorder

Summary: in this study, the sixty mechanically ventilated class i obese patients were divided into two equal groups a and b. group a received rtp position + peep protocol, while group b underwent rtp position protocol only. the results showed that the group a protocol has positive effects on the improvement of respiratory mechanics by significant increase the arterial oxygen partial pressure (pao2) in mmhg to fractional inspired oxygen (fio2), (pao2/fio2 ratio), partial pressure of carbon dioxide (paco2), and static compliance (cstat) parameters. moreover, a significant decrease in hemodynamics of bp\& map was measured. while the results of the group b protocol demonstrated a non-significant increase in the pao2/fio2 ratio, paco2, and cstat. besides, non-significant decreases in hemodynamics of blood pressure (bp) \& mean arterial blood pressure (map) were recorded.

objective to investigate the effect of the positive end-expiratory pressure (peep) titration maneuver with reverse trendelenburg position (rtp) on the respiratory and hemodynamic parameters of mechanically ventilated obese patients. design randomized, control trial. participants thirty mechanically ventilated obese patients were randomized equally as a group a to receive reverse trendelenburg position (rtp) + positive end expiratory pressure (peep) titration, and group (b): receive reverse trendelenburg position (rtp). intervention after post-operative bariatric surgeries, the sixty mechanically ventilated obese patients immediately receive a peep and rtp once before the weaning through the ventilator of the operation to evaluate the response of arterial blood gases before admission to the intensive care unit icu room. outcomes the primary outcomes included the respiratory parameters (pao2/fio2 ratio, paco2, cstat), and the secondary outcomes included the hemodynamics parameters (systolic blood pressure (sbp), diastolic blood pressure (dbp), mean arterial blood pressure (map)).

Eligibility criteria:
inclusion criteria: * subjects included in this study had the following criteria: 1. mechanically ventilated obese patients in operation room undergoing upper abdominal surgeries (bariatric) and under general anesthesia. 2. obese patients with bmi (30-34.9). 3. age 40-50 years old. 4. both sexes. 5. non-smoker. 6. no history of disease affecting the heart \& lungs. exclusion criteria: * subjects with any of the following were excluded from the study: 1. severe head injury. 2. increase intracranial pressure and who are potentially liable to develop pathologically raised intracranial pressure. 3. acute pulmonary edema. 4. barotrauma/volutrauma. 5. un-drained pneumothorax/hemothorax. 6. flail chest. 7. low blood pressure (systolic less than 80 mmhg). 8. oxygen saturation is less than 90%.

Keywords: positive end-expiratory pressure titration mechanical ventilator respiratory and hemodynamics parameters obese patients reverse trendelenburg position.
retrospective evaluation of risk factors for lower outcomes after vitrectomy with ilm flap technique

Conditions: Macular Holes

Summary: a retrospective review of medical charts of patients having undergone vitrectomy with ilm peeling and ilm flap technique for macular hole repair.

a retrospective review of medical charts of patients having undergone vitrectomy with ilm peeling and ilm flap technique for macular hole repair. pre- and postoperative oct and visual acuity in the time period up to 6 months after surgery are reviewed and possible risk factors for failed macular hole closure or lower visual acuity outcome after surgery are assessed.

Eligibility criteria:
inclusion criteria: * vitrectomy with ilm peeling and ilm flap technique in the time period form 1.1.2015 to 31.4.2020 * age 18 or older exclusion criteria: * age \<18
screening for advanced liver fibrosis using non-invasive tests in primary care

Conditions: Hepatic Fibrosis

Summary: liver fibrosis screening is possible at the asymptomatic stage through a healthcare management strategy currently recommended for patients with risk factors for chronic liver disease. it is based on a sequential strategy involving a 1st-line test, fibrosis score calculation (fib-4). given this opportunity to identify advanced fibrosis in asymptomatic patients, the project aims to set up this screening program in the grenoble area with biogroup laboratories, in collaboration with the hepato-gastroenterology department (hge) of grenoble university hospital. the aim of this study is to evaluate the success of sequential screening using fib-4, followed by a specialized fibrosis test for the diagnosis of advanced hepatic fibrosis


Eligibility criteria:
inclusion criteria: * patients between 18 and 70 years of age * fib-4 2.67 * patients covered by health insurance system exclusion criteria: * prescription triggering fib-4 emanate from a hepatogastroenterologist or oncologist * conditions associated with high risk false-positive fib-4: asat or alat \> 300 iu/l, platelets \ 500 g/l. * patient refusing to participate * subjects under guardianship or deprived of liberty
intravenous immunoglobulin for acute intracranial hemorrhage

Conditions: Intracranial Hemorrhage, Hypertensive

Summary: this pilot study aims to investigate whether intravenous immunoglobulin is safe and effective in alleviating perihematomal edema and neurologic deficits in patients with intracranial hemorrhage.

the trial consists of two groups: ivig group and control group. thirty patients will be recruited into ivig group. thirty patients who are matched for age, gender, national institutes of health stroke scale scores, hematomal volumes, and locations of hematomas, will be selected into control group. patients in control group just receive standard management, while those in ivig group will receive standard management plus intravenous immunoglobulin therapy. the outcome assessor is blinded to the group assignments.

Eligibility criteria:
inclusion criteria: 1. the first-ever primary supratentorial intracerebral basal ganglia hemorrhage 5-30ml. 2. 18-80 years old. 3. no longer than 72 hours from the acute ich to medication. 4. glasgow coma score ≥8. exclusion criteria: 1. occurrences of secondary intracerebral hemorrhage. 2. significant past history of disability, modified rankin scale（mrs）≥1. 3. currently taking antitumor drugs, immunosuppressive drugs, or immunomodulatory therapy. 4. patients with pregnancy, severe infection, severe heart dysfunction or renal and hepatic injuries. 5. patients with contraindications for immunoglobulin.

Keywords: intravenous immunoglobulin intracerebral hemorrhage perihematomal edema
confocal laser endomicroscopy for the diagnosis of gastric intestinal metaplasia, intraepithelial neoplasia, and carcinoma

Conditions: Gastric Intestinal Metaplasia; Gastric Intraepithelial Neoplasia; Gastric Carcinoma

Summary: i. to determine whether confocal laser endomicroscopy (cle) with optical biopsy and targeted mucosal biopsy improves the diagnostic yield of gastric im/in/ca in high risk populations compared to wle with standard biopsy protocol. ii. to determine whether cle with optical biopsy and targeted biopsy, as compared to wle with standard biopsy, can reduce the number of biopsies needed per patient for detection of gastric im/in/carcinoma without the loss of corresponding diagnostic yield. iii. to compare the sensitivity and specificity of cle with wle for the detection of gastric im/in/ca.

gastric cancer remains the world's second leading cause of cancer-related deaths. the prognosis for patients with this cancer clearly depends on stage at diagnosis. at least for the intestinal subtype of gastric adenocarcinoma, a cascade of histopathologic lesions has been defined: chronic gastritis, atrophic chronic gastritis, intestinal metaplasia (im), and intraepithelial neoplasia (in). the identification of these lesions and follow-up of patients in whom they are found could lead to diagnosis of gastric cancer at an early stage, thus improving patients' survival. the diagnosis of these lesions, which often appear in flat mucosa, is currently based on histopathologic examination of endoscopic biopsy specimens. however, conventional white-light endoscopy (wle) for this purpose has high interobserver variability and a poor correlation with histopathologic finding. confocal laser endomicroscopy (cle), producing both conventional wle and confocal microscopic images, can provide a direct histological observation of the in vivo tissue without the need for biopsy. recently, cle has shown its value for diagnosing gastric im, intraepithelial neoplasia and carcinoma. however, none of those cle criteria for gastric im, in or carcinoma (ca) has been validated in various endoscopic centers, hence reducing the reliability and clinical application of them.

Eligibility criteria:
inclusion criteria: * male or female aged 18-80 * patients with h. pylori infection, or histologically verified gastric intestinal metaplasia, low-grade intraepithelial neoplasia, and atrophic gastritis exclusion criteria: * patients with gastrectomy, acute gi bleeding, and advanced gastric cancer * patients under conditions unsuitable for performing cle including coagulopathy, impaired renal function, pregnancy or breastfeeding, and known allergy to fluorescein sodium * inability to provide informed consent and other situations that could interfere with the examination protocol

Keywords: confocal laser endomicroscopy gastric intestinal metaplasia gastric intraepithelial neoplasia gastric carcinoma
efficacy and tolerance evaluation of a "revitalizing" face treatment

Conditions: Face Aging/Photo Aging of Moderate Grade

Summary: efficacy and tolerance evaluation of a"revitalizing" face treatment consisting of a day and a night cream

aim of the study was to evaluate clinically and by non-invasive instrumental evaluations the activity of a "revitalizing" face treatment consisting of a day and a night cream, applied for an uninterrupted period of 3 months, by female volunteers, aged 35-60 years, with aging/photo aging of moderate grade.

Eligibility criteria:
inclusion criteria: * female sex, * age 35-60 years, * caucasian subjects, * presence of moderate face ritidosis, * agreeing to present at each study visit without make-up, * accepting to follow the instructions received by the investigator, * accepting to not change their habits regarding food, physical activity, face cleansing and make- up use, * agreeing not to apply or take any product or use face massages or other means known to improve skin wrinkle and skin qualities during the entire duration of the study, * accepting not to expose their face to strong uv irradiation (uv session, or sun bathes), during the entire duration of the study, * no participation in a similar study currently or during the previous 3 months * accepting to sign the informed consent form. exclusion criteria: * pregnancy, * lactation, * sensitivity to the test products or their ingredients (to be assessed by the investigator during the baseline visit), * subjects whose insufficient adhesion to the study protocol is foreseeable. * presence of cutaneous disease on the tested area as lesions, scars, malformations, * recurrent facial/labial herpes, * clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.). * endocrine disease, * hepatic disorder, * renal disorder, * cardiac disorder, * pulmonary disease, * cancer, * neurological or psychological disease, * inflammatory/immunosuppressive disease, * drug allergy. * anti-inflammatory drugs, anti-histaminic, topic (application on the face) and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of hormonal treatment starting more than 1 year ago), * using of drugs or dietary supplements able to influence the test results in the investigator opinion.
diaphragm protective ventilation in the intensive care unit

Conditions: Critical Illness; Muscle Weakness; Muscle Damage; Respiration, Artificial; Respiratory, Diaphragm

Summary: due to an accident, pneumonia or surgery, patients can have severe shortness of breath or lung damage to such an extent that it compromises vital functions. at such times, mechanical ventilation can be lifesaving. the ventilator temporarily takes over the function of the respiratory muscles to ensure adequate uptake of oxygen and removal of carbon dioxide. mechanical ventilation can usually be stopped quickly after the initial disease has been treated. unfortunately, in up to 25-40% of ventilated patients it takes several days to weeks before mechanical ventilation can be discontinued, even after treatment of the initial disease. this phenomenon is termed weaning failure. weakness of the respiratory muscles, such as the diaphragm, is one of the leading causes of weaning failure. like other skeletal muscles, the diaphragm can become weakened if it is used too little. this happens often during mechanical ventilation because of excessive assistance provided by the ventilator or use of sedative medication. excessive activity of the diaphragm can also lead to damage and weakness, just like in other muscles that have to perform excessive amounts for a prolonged period of time. additionally, excessive work by the diaphragm might have a direct damaging effect on the lungs, which leads to a vicious cycle. as such, it is very important to find a balance between resting the diaphragm (which may lead to weakness) and placing excessive work on the diaphragm (which can damage the diaphragm and possibly the lungs). in this study, the investigators want to test whether insufficient activity and excessive activity of the diaphragm during mechanical ventilation can be prevented or reduced. the investigators plan to measure the diaphragm activity in 40 participants on mechanical ventilation. participants will be randomly assigned to the intervention group or the control group. in the intervention group, ventilator support levels will be adjusted according to the observed diaphragm activity, in an attempt to ensure adequate diaphragm activity. the control group receives usual care. the hypothesis is that adjusting the level of support provided by the ventilator is a feasible method to improve the time that the diaphragm operates within acceptable levels of activity over a 24 hour period.


Eligibility criteria:
inclusion criteria: * informed consent * receives partially supported mechanical ventilation * estimated duration of mechanical ventilation after inclusion of at least 24 hours, as estimated by the attending physician exclusion criteria: * known neuromuscular disease * contra-indications for nasogastric intubation (upper airway surgery, bleeding disorders) * expected difficulties in obtaining reliable pressure measurements, such as known airleak into pleural space or diaphragmatic herniation

Keywords: critical illness associated diaphragm weakness mechanical ventilation critical illness respiratory muscle dysfunction
validation and pertinence of anxiety analogic visual scale in pain management

Conditions: Anxiety; Pain

Summary: screening of anxiogenic part of pain is an imperative during a medical pain consultation. the actual tools for evaluation of this specific part are complex and time consuming. to date, it lacked a reliable and reproductive tool to quickly evaluate anxiety of patient in pain. the purpose of this study is to demonstrate the pertinence and validity of anxiety analogic visual scale by comparison with the actual reference the self-assessment questionnaire state trait inventory anxiety y-a form.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent * male or female aged from ≥ 18 years old * perfect patient ability to understand and write french * patient with a pain threshold permitting a initial medication free consultation and completion of anxiety surveys. exclusion criteria: * inability of patient to understand the study procedures and thus inability to give informed consent.

Keywords: anxiety analogic visual scale pain state trait inventory anxiety scale anxiety
clinical evaluation of long-term sequelae in patients with severe plasmodium falciparum malaria

Conditions: Falciparum Malaria

Summary: malaria, endemic in 85 countries, remains a major concern. by 2022, there will be 249 million cases and 608,000 deaths, 94% of them in africa. in france, 4995 cases of imported malaria were reported in 2021, with 15% of severe forms and a fatality rate of 2.5%. long-term sequelae, such as kidney failure and neurological disorders, are well documented in children, but few studies have focused on adults. our main objective is to describe and estimate the frequency of long-term sequelae of severe imported malaria treated at our centre. our aim is to compare long-term neurological sequelae between neuromalaria and severe malaria without neurological disorders. in addition, we aim to identify the clinical, radiological and biological factors associated with sequelae in order to improve post-hospitalisation follow-up. finally, we aim to describe acute complications arising at diagnosis and during hospitalisation.


Eligibility criteria:
inclusion criteria: * male or female over 18 years of age * have been diagnosed with severe malaria according to who criteria and have been treated between 1/1/2018 and 321/12/2024 at the ap-hm * have been treated with artesunate iv (malacef®) (at least one dose) * patient who has received information about the study and has not expressed opposition * patient benefiting or entitled to benefit from a social security scheme exclusion criteria: * patients with advanced neurodegenerative pathology pre-existing the malaria attack * subjects covered by articles l1121-5 to 1121-8 of the public health code (minor patients, patients of legal age under guardianship, curatorship or safeguard of justice, patients deprived of their liberty, pregnant or breast-feeding women), * persons who do not understand french
v2 receptor effects on fluid regulation and performance

Conditions: Electrolyte Imbalance; Hyponatremia; Hypernatremia

Summary: this primary aim of this study was to critically assess whether or not sweat water content and sodium concentration were acutely regulated by dynamic changes in antidiuretic hormone (arginine vasopressin or avp) acting on the vasopressin 2 receptor (v2r) during exercise. secondary aims were to evaluate running performance and core temperature to further characterize the role of avp in the coordinated balance of fluid and temperature homeostasis during exercise. the primary hypothesis was that activation of the v2r in sweat glands would result in water reabsorption and fluid conservation during endurance exercise.

ten healthy habitual runners (\> 50km running per week) between 18-60 years of age participated in this double blind randomized control trial. each subject presented to the exercise lab on four separate occasions. trial 1 was a familiarization trial to determine each subject's maximal aerobic capacity and peak treadmill running speak (vo2 peak test). trials 2, 3 and 4 utilized the same exact protocol, differing only in pharmacological intervention. in a randomized, double-blind order (both participant and investigator blinded to the intervention), either a placebo pill, the v2 receptor antagonist tolvaptan (samsca™, 30mg tablet), or the v2 receptor agonist desmopressin (ddavp™, 0.2mg tablet) was ingested along with the cortemp™ core temperature sensor two hours before commencement of the exercise trial with 240ml of bottled water. the exercise protocol consisted of 60 minutes of treadmill running at 60% of peak speed (steady-state) followed by a performance test (the vo2 peak test). blood, saliva and urine, were collected before the exercise trial (baseline) and again after both the steady-state run and performance runs. sweat was obtained from sweat patches after both the steady-state and performance runs. core temperature, fluid intake, performance time, body weight, thirst and sodium palatability ratings were also assessed. free access to water was allowed during the trial and all urine produced during the trial was measured and collected. the main outcome measure was sweat sodium concentration.

Eligibility criteria:
inclusion criteria: * healthy (no acute or chronic medical conditions or regular prescription medication use), habitual (\>50km/week) * distance runners between the ages of 18-60 years. exclusion criteria: * individuals with chronic medical problems which require regular prescription medication * runners with pre-existing kidney problems * unable to sense thirst * difficulty swallowing * gastrointestinal disorders * history of fainting associated with blood draw.

Keywords: arginine vasopressin sweat sodium v2 antagonist running
mri in ductal carcinoma in situ (dcis)

Conditions: Ductal Carcinomas

Summary: compare the estimate of the lesional size in mri to that in mammography, taking as a reference the definitive anatomo-pathological size


Eligibility criteria:
inclusion criteria: * age ≥18 ans * woman with dcis exclusion criteria: * age ≥18 ans)

Keywords: ductal carcinomas ductal carcinoma in situ (dcis) mri